Right Drug, Right Dose, Right Time - Using Genomic Data to Individualize Treatment
Right Drug, Right Dose, Right Time - Using Genomic Data to Individualize Treatment
This study is being done to better understand how genetic information related to drug dosing
 and use can affect medical care of patients. By doing this study, the investigators are
 developing and improving ways to incorporate information about drug related genetic variants
 into the medical record.
The purpose of this research is to initiate a test of the concept that sequence information
 can be coupled to electronic medical records (EMRs) for use in healthcare.The focus of this
 study is on pharmacogenomics, given the role of adverse drug reactions (ADRs) as major causes
 of morbidity and mortality, the increasing number of recognized variants included in FDA
 labels as mediators of both efficacy and toxicity, and the relative lack of stigma attached
 to carriers of variants in "pharmacogenes". Preemptive sequencing of patients interrogates
 large numbers of PGx variants and integrates clinically actionable results in a patient's
 electronic health record (EHR) for use by clinicians at the point-of-care. It is unknown,
 however, whether integration of preemptive PGx data into the EHR will significantly improve
 patient outcomes and reduce healthcare costs. Therefore, the Right Drug, Right Dose, Right
 Time Using Genomic Data to Individualize Treatment Protocol (RIGHT Protocol) study was
 designed to recruit a large group of patients for preemptive PGx testing, to develop the EHR
 infrastructure to deliver clinical decision support in real time, and to study the effects of
 integrating preemptive PGx testing into clinical practice on patient outcomes.
Inclusion Criteria:

 -  Biobank participants who receive the majority of their care at Mayo Clinic based on
 EHR length and depth.

 Exclusion Criteria:

 -  Not in the Mayo Clinic Biobank. Do not receive the majority of their care at a Mayo
 Clinic site.